NAD+ Without Prescription: Category 1 Is Not Approval

Summary: Three routes to the same coenzyme sit on three different legal footings, and the FDA category that makes NAD+ unusual among research compounds is routinely misreported as either an approval or a ban when it is neither.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Buying NAD+ without prescription is the ordinary way it changes hands, and the reason is not a loophole. NAD+ is a coenzyme sold for laboratory research, and that transaction never involves a prescriber. What surprises people is the second half of the picture: unlike most compounds this site covers, NAD+ also has a legitimate prescription route, and getting the difference right is the whole of this page.

This is the most careful page in our NAD+ coverage, because the regulatory position is genuinely unusual and it is misreported in both directions. Some pages call it approved. Others call it prohibited. Neither is true.

NAD+ without prescription: three routes on three legal footings

The first row is the one people mean when they search for NAD+ with no prescription. It is real, it is how the research market works, and it is also the row with nobody standing behind the manufacturing. The other two rows involve a prescriber and a pharmacy, which is a genuine difference from retatrutide, MOTS-c or BPC-157, where no lawful prescription route exists at all. Our page on BPC-157 without a prescription is the contrast case, and it is a useful one to read alongside this.

What FDA category 1 actually means

NAD sits in a specific place in the federal compounding framework, and the detail matters.

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may use a bulk drug substance only if it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list. While it evaluates the substances nominated for that list, the FDA runs an interim policy sorting nominations into three categories ^[1].

On the category lists updated 14 May 2026, Nicotinamide Adenine Dinucleotide (NAD) appears in category 1, "Bulk Drug Substances Under Evaluation". So does Nicotinamide Adenine Dinucleotide Disodium Reduced, the reduced form usually written NADH ^[2].

Here is what category 1 means, in the FDA's own words: "FDA does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1, provided that the conditions described in the guidance document are met." ^[1]

Three things follow, and all three get lost in the retelling.

• It is a statement of enforcement intent, not an approval. There is no approved NAD+ drug product behind it, no label, and no efficacy finding.
• It is explicitly interim. The heading is under evaluation, and the list is revised as the agency works through nominations, which is why it carries an update date at all.
• It applies to compounders, not to consumers. Category 1 does not make a research vial into a medicine, and it does not create a right to buy anything.

The Beta-NAD trap

There is one entry that looks like the same substance under a longer name and sits somewhere else entirely. Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate appears in category 3, "Bulk Drug Substances Nominated Without Adequate Support" ^[2].

Category 3 means the nomination did not arrive with enough information for the agency to evaluate it, which is a statement about paperwork rather than a safety finding. But the practical effect is that a name most readers would treat as interchangeable carries a different status. If you are checking a compounder's claim, or reading a page that cites a category number, check which entry is being cited before you accept the conclusion.

Is NAD+ legal to buy?

For research material, the honest answer is that the sale is legal in the form it is offered, which is laboratory research material not for human consumption, and that the frame is doing a lot of work. The label is what keeps the transaction outside the drug approval system. Buying it is not the risky part. Treating a research chemical as a medicine is the part the label exists to disclaim, and the seller has told you in writing that they are not standing behind that use.

There is no prescription to seek for that route, because there is nothing to prescribe. A prescriber writing for NAD+ is writing for a compounded preparation from a pharmacy, which is the second row of the table above and a different product with a different chain of custody.

Precursor molecules such as NMN and NR come up constantly in this discussion. They are different substances with their own separate regulatory histories, which we have not verified here and will not summarise from memory. What is fair to say is that a bottle of precursor capsules from a supplement shelf and a gram of NAD+ sold for laboratory research are not the same purchase and are not governed by the same rules.

The requirement that survives every route

Whatever footing you are on, one criterion does not move, and it is the one with adverse events behind it.

The FDA published a compounding notice, current as of 30 October 2024, stating that it was aware of compounders using food-grade nicotinamide adenine dinucleotide sold by repackagers to make intravenous products, and that ingredients identified as food grade are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins. It reported adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue, some requiring medical treatment, and described those reactions as consistent with excessive levels of endotoxins ^[3].

Notice how that interacts with the categories. Category 1 says the agency does not currently intend to act against a compounder using NAD as a bulk substance. It says nothing about the grade of the powder that compounder bought. The rules on the legitimate side close that gap by requiring bulk drug substances to arrive with a valid certificate of analysis from an FDA-registered establishment ^[1], and by making compounding oversight a shared federal and state responsibility ^[4]. A research buyer has none of that machinery, which is why the certificate is the entire inspection you get: pharmaceutical grade rather than food grade, matched to your lot, and reporting a bacterial endotoxin or LAL result rather than identity and purity alone.

What none of this settles

Legal footing is not evidence. A 2026 PRISMA-guided systematic review of NAD-related interventions identified 113 eligible studies, including 33 human intervention studies, and found that oral precursors reliably engaged their biochemical target while effects on functional and metabolic outcomes were heterogeneous and often null. On the injectable route specifically, it reported that no eligible outcomes trials evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness indications ^[5].

That is worth holding next to the category discussion. A substance can be lawfully compoundable under an interim policy and still lack the trials people assume produced the marketing. This site does not publish dosing for research material, and the reason is the same one: there is no validated human dosing to publish.

We earn a commission if you use the link on the card above, disclosed there and in our disclaimer. For the sourcing checklist see where to buy NAD+, and for what a local clinic is selling see NAD+ near me.

Questions about NAD+ and prescriptions

Do I need a prescription to buy NAD+?

Not for research-grade material, which is sold for laboratory use rather than human use and involves no prescriber. A compounded, finished NAD+ preparation for a person is a different product and does require a prescription.

Can a doctor actually prescribe NAD+?

A prescriber can write for a compounded preparation, and a 503A pharmacy can compound using NAD as a bulk substance under the FDA's interim category 1 policy. That is enforcement discretion pending evaluation, not an approval of a drug product.

Is NAD+ prohibited for use in compounding?

No. That claim usually comes from confusing the categories. On the list updated 14 May 2026, NAD and NADH are in category 1, and category 2 holds six other substances, none of which is NAD.

Why does Beta-NAD show up in a different category?

Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate is a separate entry and sits in category 3, meaning it was nominated without enough supporting information for FDA to evaluate. The similar name is not evidence of the same status.

Is NAD+ legal to buy in the United States?

Research material is sold openly under a not-for-human-use label, which is the frame that keeps it outside the drug approval system. It is not an approved medicine, and the label is a disclaimer of the use most buyers have in mind.

If the FDA permits compounding, does that mean it is safe to inject?

No. The FDA's own notice describes compounders using food-grade NAD+ to make intravenous products and links the resulting reactions to excessive endotoxin levels. Category status is about compounding policy, grade and endotoxin testing are about what is in the vial.

The short version

NAD+ without prescription describes the research-use market, which is how most of it is bought and which carries no prescriber and no accountability for manufacture. A prescription route also exists, which is unusual for a compound covered on this site, and it rests on an FDA interim policy that lists NAD in category 1, meaning under evaluation with enforcement discretion, not approval and not permanence. Beta-NAD sits in category 3 under a nearly identical name. None of that answers the question that produced actual harm reports, which is whether the material was pharmaceutical grade and whether anybody tested it for endotoxin.